DexCom, Inc. (NASDAQ:DXCM) Shares Sold by Bessemer Group Inc.

Bessemer Group Inc. reduced its position in DexCom, Inc. (NASDAQ:DXCM) by 28.0% in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 955,161 shares of the medical device company’s stock after selling 372,228 shares during the quarter. Bessemer Group Inc.’s holdings in DexCom were worth $132,480,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of DexCom by 0.3% in the first quarter. Vanguard Group Inc. now owns 44,603,745 shares of the medical device company’s stock worth $6,186,539,000 after buying an additional 136,282 shares in the last quarter. Capital Research Global Investors lifted its stake in DexCom by 21.4% in the 4th quarter. Capital Research Global Investors now owns 15,296,032 shares of the medical device company’s stock worth $1,898,085,000 after purchasing an additional 2,695,296 shares in the last quarter. Sands Capital Management LLC boosted its holdings in shares of DexCom by 10.2% during the 4th quarter. Sands Capital Management LLC now owns 15,058,806 shares of the medical device company’s stock worth $1,868,647,000 after purchasing an additional 1,398,136 shares during the last quarter. Capital World Investors grew its position in shares of DexCom by 130.7% in the fourth quarter. Capital World Investors now owns 9,278,685 shares of the medical device company’s stock valued at $1,151,392,000 after purchasing an additional 5,256,092 shares in the last quarter. Finally, Artisan Partners Limited Partnership grew its position in shares of DexCom by 164.8% in the fourth quarter. Artisan Partners Limited Partnership now owns 5,900,308 shares of the medical device company’s stock valued at $732,169,000 after purchasing an additional 3,672,471 shares in the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insider Activity

In related news, EVP Sadie Stern sold 427 shares of the business’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $49,126.35. Following the completion of the transaction, the executive vice president now directly owns 75,877 shares of the company’s stock, valued at approximately $8,729,648.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, Director Bridgette P. Heller sold 1,000 shares of the firm’s stock in a transaction on Friday, June 14th. The shares were sold at an average price of $113.55, for a total value of $113,550.00. Following the sale, the director now directly owns 25,349 shares in the company, valued at approximately $2,878,378.95. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Sadie Stern sold 427 shares of the business’s stock in a transaction on Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $49,126.35. Following the transaction, the executive vice president now owns 75,877 shares of the company’s stock, valued at approximately $8,729,648.85. The disclosure for this sale can be found here. Over the last three months, insiders have sold 4,112 shares of company stock worth $480,861. Corporate insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

DXCM has been the topic of a number of recent research reports. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research note on Monday, June 10th. UBS Group boosted their price target on shares of DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Stifel Nicolaus dropped their price objective on shares of DexCom from $145.00 to $132.00 and set a “buy” rating for the company in a report on Friday, July 12th. Morgan Stanley reduced their target price on shares of DexCom from $132.00 to $120.00 and set an “equal weight” rating on the stock in a research note on Monday, July 15th. Finally, Redburn Atlantic assumed coverage on shares of DexCom in a research note on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price target for the company. Four analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $139.33.

DexCom Trading Down 0.2 %

NASDAQ:DXCM traded down $0.19 on Wednesday, reaching $111.94. 3,614,746 shares of the company’s stock were exchanged, compared to its average volume of 2,860,668. The firm has a market capitalization of $44.52 billion, a price-to-earnings ratio of 72.22, a price-to-earnings-growth ratio of 2.73 and a beta of 1.16. DexCom, Inc. has a 52-week low of $74.75 and a 52-week high of $142.00. The company has a quick ratio of 2.53, a current ratio of 2.90 and a debt-to-equity ratio of 1.08. The business has a fifty day moving average of $117.46 and a 200-day moving average of $124.49.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.05. DexCom had a net margin of 16.82% and a return on equity of 31.01%. The firm had revenue of $921.00 million for the quarter, compared to the consensus estimate of $911.20 million. As a group, analysts expect that DexCom, Inc. will post 1.78 earnings per share for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.